Background High serum levels of interleukin 6 (IL-6) predict poor prognosis in intrahepatic cholangiocarcinoma (iCCA), a ...

The 10th Annual Smithies Symposium will take place on Thursday, March 26 from 3 to 4:30 p.m. (doors open at 2:30 p.m.) in the ...

In this article, we will discuss Cathie Wood’s 2026 Portfolio: 10 Best Stocks to Buy. Ark Invest CEO Cathie Wood quickly ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Key Points ARKK surged 153% in 2020 then plunged 67% in 2022 before recovering 37.33% in the last year. Tesla remains Wood’s largest position at $1.3B, representing 9% of the fund. Wood kept buying ...

I was born in Washington, DC, in 1964, the oldest of three sisters, but the place that truly formed me as a scientist was Hilo, on the Big Island of Hawaii. Growing up there, far from the mainland ...

CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient ...

Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments ...

Gene editing is a numbers game. For any genetic tweaks to have notable impact, a sufficient number of targeted cells need to have the disease-causing gene deleted or replaced. Despite a growing ...

Antibiotic resistance (AR) has steadily accelerated in recent years to become a global health crisis. As deadly bacteria evolve new ways to elude drug treatments for a variety of illnesses, a growing ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

A new CRISPR-based one-off procedure that lowers "bad" cholesterol is expected to enter Phase I human trial in 2026. If successful, it could be the first approved genetic-silencing method on the ...